Standard Care | Low Risk

NEOMYCIN SULFATE, POLYMYXIN B SULFATE, AND DEXAMETHASONE (Neomycin and Polymyxin B Sulfates and Dexamethasone)

What to know about NEOMYCIN SULFATE, POLYMYXIN B SULFATE, AND DEXAMETHASONE — also sold as Neomycin and Polymyxin B Sulfates and Dexamethasone: uses, side effects, interactions, and safety considerations for people taking it or caring for someone who is.

NEOMYCIN SULFATE, POLYMYXIN B SULFATE, AND DEXAMETHASONE (brand names: Neomycin and Polymyxin B Sulfates and Dexamethasone) is classified as Low risk (1 risk points) by AllMeds. It is a S4 medication under the TGA in Australia. FDA approved in the United States. Topical antibiotic-corticosteroid combination with minimal systemic absorption.

Key Takeaways

  • TGA Schedule: S4 in Australia
  • Risk level: Low (1 points)
  • Recommended maximum duration: 14 days

Scheduling and Classification

Jurisdiction Classification Status
Australia (TGA) S4 Not PBS listed
United States (FDA) Rx only FDA approved

Risk Profile

Risk Level Low
Risk Points 1
CNS Depressant No
Respiratory Risk No
Max Duration 14 days

Topical antibiotic-corticosteroid combination with minimal systemic absorption.

How NEOMYCIN SULFATE, POLYMYXIN B SULFATE, AND DEXAMETHASONE is regulated

NEOMYCIN SULFATE, POLYMYXIN B SULFATE, AND DEXAMETHASONE is overseen by medicines regulators in each country. The rules below explain how it's scheduled, what oversight applies, and what to discuss with your doctor or pharmacist before starting, changing, or stopping this medication.

Australia TGA / PBS / State Schemes

Classified as S4 under the Therapeutic Goods Administration (TGA).

SIRA best practice guidelines recommend a maximum opioid duration of 14 days for acute pain. Prescribing beyond this requires documented clinical justification and may trigger a Reasonable and Necessary determination.

WorkSafe Victoria Drugs of Dependence Guidelines require monitoring for all S8 opioids. WorkCover QLD Pain Intervention Guidelines recommend multimodal pain management with opioids as a last resort.

United Kingdom NICE / MHRA / FPM

NICE NG193 (Chronic Pain) recommends against initiating opioids for chronic primary pain. The Faculty of Pain Medicine (FPM) Opioids Aware resource recommends structured opioid prescribing with regular review, dose limits, and documented tapering plans.

For personal injury claims in the UK, opioid prescribing duration and dose should be reviewed against NICE and FPM guidelines. Costs may be recoverable as a disbursement in high-value PI claims.

United States FDA / CDC / State WC

FDA approved for use in the United States.

The CDC Clinical Practice Guideline for Prescribing Opioids (2022) recommends non-opioid therapies as first-line treatment for pain. When opioids are prescribed, the lowest effective dose should be used for the shortest duration needed.

For workers compensation claims, many states require prior authorization for opioids beyond initial acute prescribing. State drug formularies (e.g. California MTUS, Texas, New York) may restrict or require step therapy before opioid approval.

New Zealand ACC / BPAC NZ / Medsafe

BPAC NZ recommends reassessing opioid therapy at regular intervals and limiting duration. The NZ Opioid Prescribing B-QuiCK Guide provides structured prescribing and tapering protocols.

ACC (Accident Compensation Corporation) covers treatment-related medications for accepted claims. Opioid prescribing beyond guidelines may require ACC clinical review and approval.

Check this medication against your full medication list

Run a full risk assessment including NEOMYCIN SULFATE, POLYMYXIN B SULFATE, AND DEXAMETHASONE interactions and compliance checks.

Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile in minutes. Free for individuals; team plans for case managers, insurers, and schemes.

Important: This page is general health information, not personal medical advice. If you have questions about your medication — including starting it, stopping it, changing the dose, or combining it with something else — speak with your doctor or pharmacist. For an emergency or suspected overdose, call your local emergency number or poison information service immediately. Information is drawn from regulator and clinical guideline sources (TGA, FDA, MHRA, NICE, PBS, CDC); see our methodology for details.